Dose-ranging Study in Patients With Type 1 Diabetes Mellitus
Public ClinicalTrials.gov record NCT02459899. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Dose-ranging, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study in Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study was to define the dose leading to desirable efficacy, as measured by the change in hemoglobin A1C (A1C) between Baseline and Week 12.
Study identification
- NCT ID
- NCT02459899
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 141 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2015 (Actual)
- Primary completion
- Aug 2016 (Actual)
- Completion
- Aug 2016 (Actual)
- Last update posted
- Feb 12, 2020
2015 – 2016
United States locations
- U.S. sites
- 17
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Lexicon Investigational Site | Concord | California | 94520 | — |
| Lexicon Investigational Site | Ventura | California | 93003 | — |
| Lexicon Investigational Site | Denver | Colorado | 80209 | — |
| Lexicon Investigational Site | Jacksonville | Florida | 32225 | — |
| Lexicon Investigational Site | Miami | Florida | 33175 | — |
| Lexicon Investigational Site | Springfield | Illinois | 62711 | — |
| Lexicon Investigational Site | Metairie | Louisiana | 70006 | — |
| Lexicon Investigational Site | Auburn | Maine | 04210 | — |
| Lexicon Investigational Site | Rockville | Maryland | 20852 | — |
| Lexicon Investigational Site | Great Falls | Montana | 59405 | — |
| Lexicon Investigational Site | Omaha | Nebraska | 68114 | — |
| Lexicon Investigational Site | High Point | North Carolina | 27265 | — |
| Lexicon Investigational Site | Columbus | Ohio | 43213 | — |
| Lexicon Investigational Site | San Antonio | Texas | 78229 | — |
| Lexicon Investigational Site | Salt Lake City | Utah | 84107 | — |
| Lexicon Investigational Site | Chesapeake | Virginia | 23321 | — |
| Lexicon Investigational Site | Manassas | Virginia | 20110 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02459899, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 12, 2020 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02459899 live on ClinicalTrials.gov.